Core Points - BioXcel Therapeutics, Inc. has entered into a securities purchase agreement for a registered direct offering of 4,000,000 shares of common stock at a price of $3.50 per share, aiming for gross proceeds of approximately $14 million [1][2] - The offering includes accompanying warrants to purchase an additional 4,000,000 shares at an exercise price of $4.20 per share, which are exercisable after issuance and expire five years from the date of issuance [1] - The offering is expected to close on March 4, 2025, and the net proceeds will be used for working capital and general corporate purposes [2] Company Overview - BioXcel Therapeutics, Inc. is a biopharmaceutical company that utilizes artificial intelligence to develop transformative medicines in neuroscience [5] - The company’s subsidiary, OnkosXcel Therapeutics, LLC, focuses on immuno-oncology drug development [5] - BioXcel employs a drug re-innovation approach, leveraging existing approved drugs and big data to identify new therapeutic indications [5]